These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 15183153)

  • 1. Antigen synthesis opens the door to a broad-spectrum AIDS vaccine.
    Creavin T
    Drug Discov Today; 2004 Jun; 9(12):507-8. PubMed ID: 15183153
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use.
    Thomson SA; Jaramillo AB; Shoobridge M; Dunstan KJ; Everett B; Ranasinghe C; Kent SJ; Gao K; Medveckzy J; Ffrench RA; Ramshaw IA
    Vaccine; 2005 Sep; 23(38):4647-57. PubMed ID: 15964105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In pursuit of carbohydrate-based HIV vaccines, part 1: The total synthesis of hybrid-type gp120 fragments.
    Mandal M; Dudkin VY; Geng X; Danishefsky SJ
    Angew Chem Int Ed Engl; 2004 May; 43(19):2557-61. PubMed ID: 15127452
    [No Abstract]   [Full Text] [Related]  

  • 4. Artificial protein vaccines with predetermined tertiary structure: application to anti-HIV-1 vaccine design.
    Eroshkin AM; Zhilkin PA; Shamin VV; Korolev S; Fedorov BB
    Protein Eng; 1993 Nov; 6(8):997-1001. PubMed ID: 7508628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In pursuit of carbohydrate-based HIV vaccines, part 2: The total synthesis of high-mannose-type gp120 fragments--evaluation of strategies directed to maximal convergence.
    Geng X; Dudkin VY; Mandal M; Danishefsky SJ
    Angew Chem Int Ed Engl; 2004 May; 43(19):2562-5. PubMed ID: 15127453
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
    Hewer R; Meyer D
    Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploiting the defensive sugars of HIV-1 for drug and vaccine design.
    Scanlan CN; Offer J; Zitzmann N; Dwek RA
    Nature; 2007 Apr; 446(7139):1038-45. PubMed ID: 17460665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting carbohydrate antigens in HIV vaccine development.
    Pashov A; Canziani G; Macleod S; Plaxco J; Monzavi-Karbassi B; Kieber-Emmons T
    Vaccine; 2005 Mar; 23(17-18):2168-75. PubMed ID: 15755589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.
    Fiorentini S; Marini E; Bozzo L; Trainini L; Saadoune L; Avolio M; Pontillo A; Bonfanti C; Sarmientos P; Caruso A
    Biopolymers; 2004; 76(4):334-43. PubMed ID: 15386266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical Platforms for Peptide Vaccine Constructs.
    Ramesh S; Cherkupally P; Govender T; Kruger HG; Albericio F; de la Torre BG
    Adv Protein Chem Struct Biol; 2015; 99():99-130. PubMed ID: 26067818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Artificial antigens for HIV vaccine design.
    Expert Rev Vaccines; 2007 Jun; 6(3):301. PubMed ID: 17542744
    [No Abstract]   [Full Text] [Related]  

  • 12. Fully synthetic carbohydrate HIV antigens designed on the logic of the 2G12 antibody.
    Krauss IJ; Joyce JG; Finnefrock AC; Song HC; Dudkin VY; Geng X; Warren JD; Chastain M; Shiver JW; Danishefsky SJ
    J Am Chem Soc; 2007 Sep; 129(36):11042-4. PubMed ID: 17711286
    [No Abstract]   [Full Text] [Related]  

  • 13. Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guérin: failures and challenges.
    Joseph J; Saubi N; Pezzat E; Gatell JM
    Expert Rev Vaccines; 2006 Dec; 5(6):827-38. PubMed ID: 17184220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A common pharmacophoric footprint for AIDS vaccine design.
    Pisterer C; Mihailescu D; Smith JC; Reed J
    J Med Chem; 2004 Jul; 47(15):3723-9. PubMed ID: 15239651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of a C-glycoside analogue of sTn: an HIV- and tumor-associated antigen.
    Kuberan B; Sikkander SA; Tomiyama H; Linhardt RJ
    Angew Chem Int Ed Engl; 2003 May; 42(18):2073-5. PubMed ID: 12746827
    [No Abstract]   [Full Text] [Related]  

  • 16. Protection by dendritic cells-based HIV synthetic peptide cocktail vaccine: preclinical studies in the SHIV-rhesus model.
    Nehete PN; Nehete BP; Manuri P; Hill L; Palmer JL; Sastry KJ
    Vaccine; 2005 Mar; 23(17-18):2154-9. PubMed ID: 15755586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and ethical consideration of AIDS vaccine.
    Veljkovic V; Prljic J; Veljkovic T
    Int Rev Immunol; 2004; 23(5-6):465-86. PubMed ID: 15370278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exclusion of HIV epitopes shared with human proteins is prerequisite for designing safer AIDS vaccines.
    Maksyutov AZ; Bachinskii AG; Bazhan SI; Ryzhikov EA; Maksyutov ZA
    J Clin Virol; 2004 Dec; 31 Suppl 1():S26-38. PubMed ID: 15567091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prime-boost strategies in DNA vaccines.
    Dale CJ; Thomson S; De Rose R; Ranasinghe C; Medveczky CJ; Pamungkas J; Boyle DB; Ramshaw IA; Kent SJ
    Methods Mol Med; 2006; 127():171-97. PubMed ID: 16988455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials.
    Coupar BE; Purcell DF; Thomson SA; Ramshaw IA; Kent SJ; Boyle DB
    Vaccine; 2006 Feb; 24(9):1378-88. PubMed ID: 16257479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.